Sept. 5, 2022, China, HANGZHOU — CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
denovoMATRIX Launches Cell Therapy Grade Consumables
DRESDEN, Germany, September. 19, 2022 /BioInformant/ — denovoMATRIX GmbH, an innovator in cell and gene therapy manufacturing, announced the launch of its animal component-free product lines at cell therapy grade (CTG). The new product lines will include documentation and traceability information for compliance with industry regulatory standards, designed for the stem cell therapy manufacturing market.
Steakholder Foods™ announces Omakase Beef Morsels, a first-of-its-kind, highly marbled 3D-printed 100% cultured beef cut
The new product is a result of the company’s recently filed patent for 3D-bioprinting technology which allows unprecedented marbling control within a consolidated structure
Sept. 7, 2022, REHOVOT, Israel — Steakholder Foods Ltd. ( Nasdaq: STKH), (formerly MeaTech 3D: $MITC) an international deep-tech food company at the forefront of the cultured meat industry, is pleased to introduce Omakase Beef Morsels, a revolutionary, richly marbled structured meat product developed using a unique 3D-printing process. Inspired by the marbling standard of Wagyu beef, Omakase Beef Morsels are an innovative culinary achievement elegantly designed as a meat lover’s delicacy for premium dining experiences.
GMP cell CDMO I Peace, Inc. succeeded in converting human dermal fibroblasts into oligodendrocyte precursor cells by direct reprogramming in joint research with Stanford University and the University of California (UCSF)
September 15, 2022, Palo Alto, California – Koji Tanabe of I Peace, Inc. and a researcher Hiroko Nobuta of the University of California, San Francisco (currently assistant professor at Rutgers University) successfully achieved the direct reprogramming: the direct and rapid transformation of Dermal fibroblasts into Oligodendrocyte precursor cells by inducing four genes into the cells. This research was jointly conducted with Prof. Wernig at Sanford University and Prof. Rowitch at UCSF. The research was published in the online edition of an academic journal “Development” on June 24th. [Read more…]
Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy
MILPITAS, Calif. — Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space. [Read more…]
- « Previous Page
- 1
- …
- 63
- 64
- 65
- 66
- 67
- …
- 144
- Next Page »